WO2007060215A2 - (r)-arylkylamino derivatives and pharmaceutical compositions containing them - Google Patents

(r)-arylkylamino derivatives and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2007060215A2
WO2007060215A2 PCT/EP2006/068867 EP2006068867W WO2007060215A2 WO 2007060215 A2 WO2007060215 A2 WO 2007060215A2 EP 2006068867 W EP2006068867 W EP 2006068867W WO 2007060215 A2 WO2007060215 A2 WO 2007060215A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
alkyl
ethyl
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/068867
Other languages
French (fr)
Other versions
WO2007060215A3 (en
Inventor
Marcello Allegretti
Alessio Moriconi
Andrea Aramini
Maria Candida Cesta
Andrea Beccari
Riccardo Bertini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe SpA
Dompe PhaRMa SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2006316452A priority Critical patent/AU2006316452B2/en
Priority to CN2006800515567A priority patent/CN101360706B/en
Priority to CA2629935A priority patent/CA2629935C/en
Priority to US12/094,837 priority patent/US8026367B2/en
Priority to EP06819736.7A priority patent/EP1951663B1/en
Priority to LTEP06819736.7T priority patent/LT1951663T/en
Priority to JP2008541751A priority patent/JP5374157B2/en
Priority to SI200632098A priority patent/SI1951663T1/en
Priority to RS20160819A priority patent/RS55192B1/en
Application filed by Dompe SpA, Dompe PhaRMa SpA filed Critical Dompe SpA
Priority to ES06819736.7T priority patent/ES2597843T3/en
Priority to HRP20161260TT priority patent/HRP20161260T1/en
Priority to DK06819736.7T priority patent/DK1951663T3/en
Priority to HK09106699.2A priority patent/HK1127592B/en
Publication of WO2007060215A2 publication Critical patent/WO2007060215A2/en
Publication of WO2007060215A3 publication Critical patent/WO2007060215A3/en
Anticipated expiration legal-status Critical
Priority to CY20161101039T priority patent/CY1118109T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Definitions

  • the present invention relates to novel compounds useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement.
  • Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement.
  • the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention of injury caused by ischemia and reperfusion.
  • C5a/C5a-desArg generated by both local complement production and amyloid activation joined with astrocyte and microglia chemotaxis and activation directly induced by C5a
  • complement inhibitors have been proposed for the treatment of neurological diseases such as Alzheimer's disease (McGeer & McGeer P L, Drugs, 55, 738, 1998).
  • complement fractions are considered a promising therapeutic target in the treatment of shock and in the prevention of rejection during organ transplant (multiple organ failure and hyperacute graft rejection) (Issekutz A.C. et al., Int. J. Immunopharmacol, 12, 1, 1990; Inagi R. et at., Immunol. Lett., 27, 49, 1991). More recently, inhibition of complement fractions has been reported to be involved in the prevention of native and transplanted kidney injuries taking account of complement involvement in the pathogenesis of both chronic interstitial and acute glomerular renal injuries. (Sheerin N.S. & Sacks S.H., Curr. Opinion Nephrol. Hypert., 7, 395, 1998).
  • Characteristic neutrophil accumulation occurs in acute and chronic pathologic conditions, for example in the highly inflamed and therapeutically recalcitrant areas of psoriatic lesions.
  • Neutrophils are chemotactically attracted and activated by the synergistic action of chemokines, IL-8 and Gro- ⁇ released by the stimulated keratinocytes, and of the C5a/C5a-desArg fraction produced through the alternative complement pathway activation (T. Terui et al., Exp. Dermatol., 9, 1, 2000).
  • novel class of "omega-aminoalkylamides of R-2-aryl- propionic acids" as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells” (WO 02/068377).
  • the novel class includes compounds ranging from selective C5a inhibitors to dual C5a/IL-8 inhibitors.
  • quaternary ammonium salts of omega-aminoalkylamides of R-2-aryl- propionic acids have been reported as selective inhibitors of C5a induced neutrophils and monocytes chemotaxis (WO 03/029187).
  • R is selected from:
  • Ra is selected from
  • Ci-C 5 -alkyl C 3 -C 6 -cycloalkyl, C 2 -Cs-alkenyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C 4 -alkyl, Ci-C 4 -alkoxy, halo-Ci-C 4 -alkoxy, hydroxy, Ci-C 4 -acyloxy, phenoxy, cyano, nitro, amino;
  • heteroaryl group selected from pyridine, pyrimidine, pyrrole, thiophene, furane, indole, thiazole, oxazole, such heteroaryl being unsubstituted or substituted with a group selected from halogen, Ci-C 4 -alkyl, Ci-C 4 -alkoxy, halo-Ci-C 4 -alkoxy, hydroxy, C 1 -C 4 - acyloxy, phenoxy, cyano, nitro, amino;
  • X represents:
  • R2 and R3 are independently: hydrogen, linear or branched Ci-C 6 alkyl, optionally interrupted by an oxygen or sulfur atom, a C3-C7 cycloalkyl, C 3 -C 6 alkenyl, C 3 - C 6 -alkynyl, aryl-Ci-C 3 -alkyl, hydroxy-C 2 -C 3 -alkyl group; or R2 and R3 together with the N atom to which they are bound, form a 3 -7 membered nitrogen heterocyclic ring of formula (III)
  • Y represents: - a single bond, CH 2 , O, S, or a N-R6 group, where R6 represents hydrogen, Ci-C 4 alkyl, Ci-C 4 acyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C 4 -alkyl, Ci-C 4 -alkoxy, hydroxy, Ci-C 4 -acyloxy, phenoxy, cyano, nitro, amino, and p represents an integer from 0 to 3;
  • R7 is Ci-C ⁇ -alkyl, C 3 -C 6 - cycloalkyl, C 2 -C 6 -alkenyl, aryl and heteroaryl;
  • Rl is linear or branched C1-C5 alkyl, C 3 -Cs cycloalkyl
  • Ar is a phenyl group unsubstituted or substituted by one or more groups independently selected from halogen, Ci-C 4 -alkyl, Ci-C 4 -alkoxy, hydroxy,
  • Preferred compounds according to the invention are those wherein:
  • Ra is selected from:
  • Ci-C 5 -alkyl C 3 -C 5 -cycloalkyl; - phenyl, 2-pyridyl, 2-thiazolyl, 2-furyl, 2-pyrrolyl, 2-thiofenyl, 2-indolyl groups;
  • Ci-C 6 - phenylalkyl group consisting of straight or branched Ci-C 6 -alkyl, Ci-C 6 - phenylalkyl group;
  • R2 and R3 are independently hydrogen, linear or branched C 1 -C 6 alkyl, C3-C7 cycloalkyl, C 3 -C 6 alkenyl, C 3 -C 6 -alkynyl; or R2 and R3 together with the N atom to which they are bound, form a 4-6 membered nitrogen containig heterocyclic ring of formula (III)
  • Y represents CH 2 , O, S, or a N-R7 group, where R7 represents hydrogen, C 1 -C 4 alkyl, C 1 -C 4 acyl, and p represents an integer from 0 to 2;
  • Rl is methyl;
  • Ar is selected from:
  • Examples of particularly preferred compounds of formula (I) are: 4- ⁇ (lR)-l-[(phenylsulfonyl)amino]ethyl ⁇ phenyl trifluoromethanesulfonate (1)
  • Ar and Rl are as above defined, have been prepared with a process comprising the steps of transforming the corresponding arylalkyl carboxylic acids in the acid azides, followed by the rearrangement of said azides in the corresponding isocyanates by Curtius reaction (March's Advanced Organic Chemistry, 5th Ed., 2001, Wiley Interscience, 1412-1413 and references therein), and final conversion of isocyanates into amines by acidic hydrolysis.
  • the carboxylic acids used as starting reagents are commercially available or prepared as described (Aureli L. et al. J. Med. Chem., 2005, 48, 2469).
  • the reaction between the amines and commercially available alkyl or arylsulfonyl chlorides or acyl chlorides is performed according well known procedures.
  • the compounds of the invention of formula (I) were evaluated in vitro for their ability to inhibit chemotaxis of polymorphonucleate leukocytes (hereinafter referred to as PMNs) and monocytes induced by the fractions of the complement C5a and C5a-desArg.
  • PMNs polymorphonucleate leukocytes
  • monocytes induced by the fractions of the complement C5a and C5a-desArg.
  • mononucleates were removed by means of sedimentation on dextran (according to the procedure disclosed by WJ. Ming et al., J. Immunol., 138, 1469, 1987) and red blood cells by a hypotonic solution.
  • the cell vitality was calculated by exclusion with Trypan blue, whilst the ratio of the circulating polymorphonucleates was estimated on the cytocentrifugate after staining with Diff Quick.
  • the chemotactic activity of the C5a was evaluated on human circulating polymorphonucleates (PMNs) resuspended in HBSS at a concentration of 1.5xlO 6 PMNs per mL.
  • the compounds of the invention in formula (I) were evaluated at a concentration ranging between 10 "7 and 10 "10 M; for this purpose they were added, at the same concentration, both to the lower pores and the upper pores of the microchamber.
  • the wells in the lower part contain the solution of C5a or the simple carrier, those in the upper part contain the suspension of PMNs.
  • the inhibition data of the chemotaxis of PMN concentration range between 10 "7 and 10 "8 M) of some representative compounds of the invention are reported in Table 1.
  • the compounds of formula (I) were evaluated ex vivo in the blood in toto according to the procedure disclosed by Patrignani et al., in J. Pharmacol. Exper. Then, 271, 1705, 1994. In almost all cases, the compounds of formula (I) do not interfere with the production of PGE 2 induced in murine macrophages by lipopolysaccharides stimulation (LPS, 1 ⁇ g/mL) at a concentration ranging between 10 "5 and 10 "7 M. Inhibition of the production of PGE 2 is mostly at the limit of statistical significance, and generally below 15-20% of the basal value.
  • the compounds of the invention are particularly useful in the treatment of diseases such as psoriasis (R. J. Nicholoff et al., Am. J. Pathol., 138, 129, 1991), bullous pemphigoid, sepsis, rheumatoid arthritis (M. SeIz et al., J. Clin. Invest., 87, 463, 1981), intestinal chronic inflammatory pathologies such as ulcerative colitis (Y. R.
  • the compounds of the invention of formula (I) are conveniently formulated in pharmaceutical compositions using conventional techniques and excipients such as those described in "Remington' s Pharmaceutical Sciences Handbook” MACK Publishing, New York, 18th ed., 1990.
  • the compounds of the invention can be administered by intravenous injection, as a bolus, in dermatological preparations (creams, lotions, sprays and ointments), by inhalation as well as orally in the form of capsules, tablets, syrup, controlled- release formulations and the like.
  • the average daily dose depends on several factors such as the severity of the disease, the condition, age, sex and weight of the patient.
  • the dose will vary generally from 1 to 1500 mg of compounds of formula (I) per day, optionally divided in multiple administrations.
  • alkyl and arylsulfonyl and the acyl chlorides used as reagents in the synthesis of compounds of formula (I) are known products, generally commercially available or they can be prepared according to methods described in the literature.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention relates to selected (R)-arylalkylamino derivatives of formula (I), in which R, R1 and Ar are as defined in the claims. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.

Description

"(R)-ARYLALKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM "
Introduction and background of the invention The present invention relates to novel compounds useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention of injury caused by ischemia and reperfusion.
In response to immunologic and infective events, activation of the complement system mediates amplification of inflammatory response both via direct membrane action and via release of a series of peptide fragments, generally known as anaphylatoxins, generated by enzymatic cleavage of the C3, C4 and C5 complement fractions. These peptides include C3a and C4a, both of 77 aminoacids; in turn, C5 convertase cleaves the C5 complement fraction to give the glycoprotein C5a of 74 aminoacids. The C5a peptide fragment of the complement has been defined as the
"complete" pro-inflammatory mediator due to its chemotactic and inflammatory activity. In fact, other inflammatory mediators such as selected cytokines (IL-8, MCP-I and RANTES, for example) are highly selective towards self- attracted cells, while others such as histamine and bradykinin are only weak chemotactic agents. Convincing evidences support the involvement of C5a, in vivo, in several pathological conditions including ischemia/reperfusion, autoimmune dermatitis, membrane-proliferative idiopathic glomerulonephritis, airway irresponsiveness and chronic inflammatory diseases, ARDS and CODP, Alzheimer's disease, juvenile rheumatoid arthritis (N.P. Gerard, Ann. Rev. Immunol., 12, 755, 1994). In view of the neuro-inflammatory potential of C5a/C5a-desArg generated by both local complement production and amyloid activation joined with astrocyte and microglia chemotaxis and activation directly induced by C5a, complement inhibitors have been proposed for the treatment of neurological diseases such as Alzheimer's disease (McGeer & McGeer P L, Drugs, 55, 738, 1998).
Furthermore, the control of the synthesis of complement fractions is considered a promising therapeutic target in the treatment of shock and in the prevention of rejection during organ transplant (multiple organ failure and hyperacute graft rejection) (Issekutz A.C. et al., Int. J. Immunopharmacol, 12, 1, 1990; Inagi R. et at., Immunol. Lett., 27, 49, 1991). More recently, inhibition of complement fractions has been reported to be involved in the prevention of native and transplanted kidney injuries taking account of complement involvement in the pathogenesis of both chronic interstitial and acute glomerular renal injuries. (Sheerin N.S. & Sacks S.H., Curr. Opinion Nephrol. Hypert., 7, 395, 1998).
Characteristic neutrophil accumulation occurs in acute and chronic pathologic conditions, for example in the highly inflamed and therapeutically recalcitrant areas of psoriatic lesions. Neutrophils are chemotactically attracted and activated by the synergistic action of chemokines, IL-8 and Gro-α released by the stimulated keratinocytes, and of the C5a/C5a-desArg fraction produced through the alternative complement pathway activation (T. Terui et al., Exp. Dermatol., 9, 1, 2000). We have recently described a novel class of "omega-aminoalkylamides of R-2-aryl- propionic acids" as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells" (WO 02/068377). The novel class includes compounds ranging from selective C5a inhibitors to dual C5a/IL-8 inhibitors.
Furthermore, quaternary ammonium salts of omega-aminoalkylamides of R-2-aryl- propionic acids have been reported as selective inhibitors of C5a induced neutrophils and monocytes chemotaxis (WO 03/029187).
Detailed description of the invention
We have now surprisingly found novel (R)-arylalkylamino derivatives which exhibit a potent and selective inhibitory effect on C5a induced human PMN chemotaxis. The present invention relates to (R)-Arylalkylamino derivatives of formula (I):
Figure imgf000004_0001
(I) wherein R is selected from:
- 2 -thiazolyl or 2-oxazolyl, unsubstituted or substituted by a group selected from methyl, tert -butyl or trifluoromethyl group;
- C(Ra)=N-W wherein W is linear or branched C1-C4 alkyl,
- CORa, SORa, SO2Ra, PORd, PO2Ra, wherein
Ra is selected from
- Ci-C5-alkyl, C3-C6-cycloalkyl, C2-Cs-alkenyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, halo-Ci-C4-alkoxy, hydroxy, Ci-C4-acyloxy, phenoxy, cyano, nitro, amino;
- a heteroaryl group selected from pyridine, pyrimidine, pyrrole, thiophene, furane, indole, thiazole, oxazole, such heteroaryl being unsubstituted or substituted with a group selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, halo-Ci-C4-alkoxy, hydroxy, C1-C4- acyloxy, phenoxy, cyano, nitro, amino;
- a α or β carboxyalkyl residue consisting of straight or branched C1- Cδ-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, Ci-Cδ-phenylalkyl, optionally substituted with a further carboxy (COOH) group;
- an ω-aminoalkylamino group of formula II:
R2 — X- N
R3
(H) wherein
X represents:
- linear or branched C1-C6 alkylene, C4-C6 alkenylene, C4-C6 alkynylene, optionally substituted by a CO2R4 group or by a C0NHR5 group, wherein R4 represents hydrogen or a linear or branched Ci-C6 alkyl group or a linear or branched C2-C6 alkenyl group, wherein R5 represents hydrogen, linear or branched C2-C6 alkyl or an OR4 group, R4 being defined as above;
- a (CH2)m-B-(CH2)n, group, optionally substituted by a CO2R4 or C0NHR5 group, as defined above, wherein B is an oxygen, or sulfur atom, or nitrogen atom optionally substituted by a Ci-C4 alkyl group, m is zero or an integer from 2 to 3 and n is an integer from 2 to 3, or B is a CO, SO or CONH group, m is an integer from 1 to 3 and n is an integer from 2 to 3; - or X together with the nitrogen atom to which it is bound and with the R2 group forms a nitrogen containing 3-7 membered heterocyclic, monocyclic or poly cyclic ring, and R3 represents hydrogen, Ci-C4 alkyl, Ci-C4 acyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, hydroxy, C1-C4- acyloxy, phenoxy, cyano, nitro, amino;
R2 and R3 are independently: hydrogen, linear or branched Ci-C6 alkyl, optionally interrupted by an oxygen or sulfur atom, a C3-C7 cycloalkyl, C3-C6 alkenyl, C3- C6-alkynyl, aryl-Ci-C3-alkyl, hydroxy-C2-C3-alkyl group; or R2 and R3 together with the N atom to which they are bound, form a 3 -7 membered nitrogen heterocyclic ring of formula (III)
Figure imgf000005_0001
wherein
Y represents: - a single bond, CH2, O, S, or a N-R6 group, where R6 represents hydrogen, Ci-C4 alkyl, Ci-C4 acyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, hydroxy, Ci-C4-acyloxy, phenoxy, cyano, nitro, amino, and p represents an integer from 0 to 3;
- a residue of formula SO2R7 wherein R7 is Ci-Cδ-alkyl, C3-C6- cycloalkyl, C2-C6-alkenyl, aryl and heteroaryl;
Rl is linear or branched C1-C5 alkyl, C3-Cs cycloalkyl;
Ar is a phenyl group unsubstituted or substituted by one or more groups independently selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, hydroxy,
Ci-C4-acyloxy, phenoxy, cyano, nitro, amino, Ci-C4-acylamino, halo-Ci- C3- alkyl, halo-Ci-C3-alkoxy, benzoyl, heteroaryl carbonyl, heteroaryl, linear or branched Ci-Cs-alkanesulfonate, linear or branched C1-Cs- alkanesulfonamides, linear or branched Ci-Cs alkyl sulfonylmethyl; or Ar is a heteroaryl ring selected from pyridine, pyrrole, tiofene, furane, indole.
Preferred compounds according to the invention are those wherein:
R is
- 2-thiazolyl, unsubstituted or substituted by a group selected from methyl or trifluoromethyl group;
- CORa, SO2Ra, SORa; wherein
Ra is selected from:
- Ci-C5-alkyl, C3-C5-cycloalkyl; - phenyl, 2-pyridyl, 2-thiazolyl, 2-furyl, 2-pyrrolyl, 2-thiofenyl, 2-indolyl groups;
- a carboxylalkyl group consisting of straight or branched Ci-C6-alkyl, Ci-C6- phenylalkyl group;
- an ω-alkylamino group of formula II, R2 X- N \
R3
(H) wherein X represents: linear or branched C1-C6 alkylene, C4-C6 alkenylene, C4-C6 alkynylene; or X together with the nitrogen atom to which it is bound and with the R2 group forms a nitrogen containing 3-7 membered heterocyclic monocyclic ring and R3 represents hydrogen or C1-C4 alkyl;
R2 and R3 are independently hydrogen, linear or branched C1-C6 alkyl, C3-C7 cycloalkyl, C3-C6 alkenyl, C3-C6-alkynyl; or R2 and R3 together with the N atom to which they are bound, form a 4-6 membered nitrogen containig heterocyclic ring of formula (III)
Figure imgf000007_0001
wherein Y represents CH2, O, S, or a N-R7 group, where R7 represents hydrogen, C1-C4 alkyl, C1-C4 acyl, and p represents an integer from 0 to 2;
Rl is methyl; Ar is selected from:
3 ' -benzoylphenyl, 3 ' -(4-chloro-benzoyl)-phenyl, 3 ' -(4-methyl-benzoyl)-phenyl, 3 '-acetyl-phenyl, 3'-propionyl-phenyl, 3'-isobutanoyl-phenyl, 4'-isobutyl- phenyl, 4' -trifluoromethanesulfonyloxy-phenyl, 4'-benzenesulfonyloxy-phenyl,
4'-trifluoromethanesulfonylamino-phenyl, 4'-benzenesulfonylamino-phenyl, 4'-benzenesulfonylmethyl-phenyl, 4'-acetoxyphenyl, 4'-propionyloxy-phenyl, 4'-benzoyloxy-phenyl, 4'-acetylamino-phenyl, 4'-propionylamino-phenyl, 4'- benzoylamino-phenyl; 3'-(furan-2-carbonyl)-phenyl; 3'-(benzofuran-2-carbonyl)-phenyl; 3'-(thiophen-
2-carbonyl)-phenyl; 3 ' -(pyridine-2-carbonyl)-phenyl, 3 ' -(thiazole-2-carbonyl)- phenyl, 3'-(oxazole-2-carbonyl)-phenyl; 3'-(2-furyl)-phenyl, 3'-(2-oxazolyl)- phenyl, 3'-(3-isoxazolyl)-phenyl, 3'-(2-benzoxazolyl)-phenyl, 3'-(3- benzoisoxazolyl)-phenyl, 3'-(2-thiazolyl)-phenyl, 3'-(2-pyridyl)-phenyl, 3'-(2- thiophenyl)-phenyl;
Examples of particularly preferred compounds of formula (I) are: 4-{(lR)-l-[(phenylsulfonyl)amino]ethyl}phenyl trifluoromethanesulfonate (1)
N-[(lR)-l-(3-benzoylphenyl)ethyl]benzenesulfonamide (2)
4-{(lR)-l-[(pyridine-3-ylsulfonyl)amino]ethyl}phenyl trifluoromethanesulfonate (3)
N-[(lR)-l-(3-benzoylphenyl)ethyl]methanesulfonamide (4)
N-[(lR)-l-[3-(2-furoyl)phenyl]ethyl}thiophene-2-sulfonamide (5) N-[(lR)-l-[3-(2-furoyl)phenyl]ethyl}methanesulfonamide (6)
4- {(1R)- 1 -[(thien-2-ylsulfonyl)amino]ethyl }phenyl trifluoromethanesulfonate (7)
N-[(lR)-l-(3-benzoylphenyl]ethyl}thiophene-2-sulfonamide (8)
N-[(lR)-l-(3-benzoylphenyl]ethyl}-3-pyrrolidin-l-ylpropane-l -sulfonamide (9) methyl 5-({[(lR)-l-(3-benzoylphenyl)ethyl]amino}sulfonyl)-2-furoate (10) 5-({[(lR)-l-(3-benzoylphenyl)ethyl]amino}sulfonyl)-2-furoic acid (11)
4-{(lR)-2-methyl-l-[(methylsulfonyl)amino]propyl}phenyl trifluoromethanesulfonate (12)
N-((lR)-l-{4-[l -methyl- l-(phenylsulfonyl)ethyl]phenyl}ethyl)methanesulfonamide
(13) 4-[(lR)-l-(isobutyrylamino)ethyl]phenyl trifluoromethanesulfonate (14)
4-{[(lR)-l-(pyridine-3-ylcarbonyl)amino]ethyl]}phenyl trifluoromethanesulfonate
(15)
N-[(lR)-l-(3-benzoylphenyl)ethyl]benzamide (16)
N-[(lR)-l-(3-benzoylphenyl)ethyl]-2-furamide (17) N-[(lR)-l-(3-benzoylphenyl)ethyl]cyclobutanecarboxamide (18)
N-[(lR)-l-(4-trifluoromethanesulfonyloxy)phenylethyl]-4-piperidin-l-ylbutanamide
(19)
4- {(1R)- 1 -[(4-pyrrolidin- 1 -ylbutanoyl)amino]ethyl] }phenyl trifluoromethanesulfonate (20) (3-{(lR)-l-[(4-trifluoramethyl-l,3-thiazol-2-yl)amino]ethyl]}phenyl)
(phenyl)methanone (21). Known methods for the preparation of formula (I) compounds have been used: the corresponding (R)-arylalkylamines of formula (IV)
R1 ^H
H
(IV)
wherein Ar and Rl are as above defined, have been prepared with a process comprising the steps of transforming the corresponding arylalkyl carboxylic acids in the acid azides, followed by the rearrangement of said azides in the corresponding isocyanates by Curtius reaction (March's Advanced Organic Chemistry, 5th Ed., 2001, Wiley Interscience, 1412-1413 and references therein), and final conversion of isocyanates into amines by acidic hydrolysis.
The carboxylic acids used as starting reagents are commercially available or prepared as described (Aureli L. et al. J. Med. Chem., 2005, 48, 2469). The reaction between the amines and commercially available alkyl or arylsulfonyl chlorides or acyl chlorides is performed according well known procedures.
The compounds of the invention of formula (I) were evaluated in vitro for their ability to inhibit chemotaxis of polymorphonucleate leukocytes (hereinafter referred to as PMNs) and monocytes induced by the fractions of the complement C5a and C5a-desArg. For this purpose, to isolate the PMNs from heparinized human blood, taken from healthy adult volunteers, mononucleates were removed by means of sedimentation on dextran (according to the procedure disclosed by WJ. Ming et al., J. Immunol., 138, 1469, 1987) and red blood cells by a hypotonic solution. The cell vitality was calculated by exclusion with Trypan blue, whilst the ratio of the circulating polymorphonucleates was estimated on the cytocentrifugate after staining with Diff Quick.
Human recombinant fractions C5a and C5a-desArg (Sigma) were used as stimulating agents in the chemotaxis experiments, giving practically identical results. The lyophilized C5a was dissolved in a volume of HBSS containing 0.2% bovin serum albumin BSA so thus to obtain a stock solution having a concentration of 10"5 M to be diluted in HBSS to a concentration of 10"9 M , for the chemotaxis assays. In the chemotaxis experiments, the PMNs were incubated with the compounds of the invention of formula (I) for 15' at 37°C in an atmosphere containing 5% CO2.
The chemotactic activity of the C5a was evaluated on human circulating polymorphonucleates (PMNs) resuspended in HBSS at a concentration of 1.5xlO6 PMNs per mL.
During the chemotaxis assay (according to W. Falket et al., J. Immunol. Methods, 33, 239, 1980) PVP-free filters with a porosity of 5 μm and microchambers suitable for replication were used.
The compounds of the invention in formula (I) were evaluated at a concentration ranging between 10"7 and 10"10 M; for this purpose they were added, at the same concentration, both to the lower pores and the upper pores of the microchamber. The wells in the lower part contain the solution of C5a or the simple carrier, those in the upper part contain the suspension of PMNs.
Inhibition of C5a-induced chemotactic activity by the individual compounds of the invention of formula (I) was evaluated by incubating the microchamber for the chemotaxis for 60 min at 37°C in an atmosphere containing 5% CO2.
Evaluation of the ability of the compounds of the invention of formula (I) to inhibit C5a-induced chemotaxis of human monocytes was carried out according to the method disclosed by Van Damme J. et al. (Eur. J. Immunol., 19, 2367, 1989). Inhibition of C5a-induced chemotactic activity by the individual compounds of the invention of formula (I) towards human monocytes was evaluated at a concentration ranging between 10"7 and 10"10M by incubating the microchamber for the chemotaxis for 120 min. at 37°C in an atmosphere containing 5% CO2.
By way of example, the inhibition data of the chemotaxis of PMN (concentration range between 10"7 and 10"8 M) of some representative compounds of the invention are reported in Table 1. The compounds of formula (I), were evaluated ex vivo in the blood in toto according to the procedure disclosed by Patrignani et al., in J. Pharmacol. Exper. Then, 271, 1705, 1994. In almost all cases, the compounds of formula (I) do not interfere with the production of PGE2 induced in murine macrophages by lipopolysaccharides stimulation (LPS, 1 μg/mL) at a concentration ranging between 10"5 and 10"7 M. Inhibition of the production of PGE2 is mostly at the limit of statistical significance, and generally below 15-20% of the basal value.
It is therefore a further object of the present invention the use of the compounds of the invention as medicaments. In view of the experimental evidences discussed above and of the role performed by the complement cascade, and namely its fraction C5a, in the processes that involve the activation and the infiltration of neutrophils, the compounds of the invention are particularly useful in the treatment of diseases such as psoriasis (R. J. Nicholoff et al., Am. J. Pathol., 138, 129, 1991), bullous pemphigoid, sepsis, rheumatoid arthritis (M. SeIz et al., J. Clin. Invest., 87, 463, 1981), intestinal chronic inflammatory pathologies such as ulcerative colitis (Y. R. Mahida et al., Clin. ScL, 82, 273, 1992), acute respiratory distress syndrome and idiopathic fibrosis (E. J. Miller, previously cited, and P. C. Carre et al., J. Clin. Invest., 88, 1882, 1991), cystic fibrosis, chronic obstructive pulmonary disease, glomerulonephritis (T. Wada et al., J. Exp. Med., 180, 1135, 1994) and in the prevention and the treatment of injury caused by ischemia and reperfusion.
To this purpose, the compounds of the invention of formula (I) are conveniently formulated in pharmaceutical compositions using conventional techniques and excipients such as those described in "Remington' s Pharmaceutical Sciences Handbook" MACK Publishing, New York, 18th ed., 1990.
The compounds of the invention can be administered by intravenous injection, as a bolus, in dermatological preparations (creams, lotions, sprays and ointments), by inhalation as well as orally in the form of capsules, tablets, syrup, controlled- release formulations and the like. The average daily dose depends on several factors such as the severity of the disease, the condition, age, sex and weight of the patient. The dose will vary generally from 1 to 1500 mg of compounds of formula (I) per day, optionally divided in multiple administrations.
The following examples illustrate the invention.
EXAMPLES
The alkyl and arylsulfonyl and the acyl chlorides used as reagents in the synthesis of compounds of formula (I) are known products, generally commercially available or they can be prepared according to methods described in the literature.
General procedure for the preparation of (lR)-l-arylethanamines intermediates.
A. (2R)-2-[(4-trifluoromethanesulfonyloxy)phenyllpropanoyl azide (2R)-2-[(4-trifluoromethanesulfonyloxy)phenyl]propanoic acid1 (8 g, 26.8 mmol) was dissolved in thionyl chloride (80 mL) and the resulting solution was refluxed until the complete disappearance of the starting material (3 h) as checked by FT-IR analysis. After cooling at room temperature, the solvent was evaporated under vacuum and toluene (15 mL) was added to the crude and evaporated twice to eliminate all the residues of thionyl chloride. To a cooled (0°-5°C) solution of the residual yellow oil in CH2Cl2 (80 mL), tetrabutylammonium bromide (40 mg, 0.12 mmol) and a solution of sodium azide (2.7 g, 41.53 mmol) in H2O (10 mL) were added and the resulting mixture was left stirring at room temperature overnight. An additional aliquot of sodium azide (1.7 g, 26.8 mmol) was added to complete the reaction. After 2 h the two phases were separated and the organic one was dried over Na2SO4, filtered and evaporated under vacuum to give an oily residue.
B. flR)-l-[H-trifluoromethanesulfonyloxy)phenyllethylamine hydrochloride The reaction was performed according a well known procedure.2 The crude acyl azide was dissolved in toluene (100 mL) and the resulting solution was refluxed until no more nitrogen was evolved. After cooling at 0°-5°C, 37% HCl (12 mL) was added and the resulting solution was heated under reflux overnight. After cooling at room temperature, H2O was added (20 mL) and the two phases were separated. The aqueous one was basified with a saturated solution of NaHCO3 to pH 8-9 and extracted with CH2Cl2 (3 x 50 mL). To the collected organic extracts a solution of acetyl chloride (1 M) in EtOH (30 mL) was added by dripping and the resulting solution was left stirring for 1 h at room temperature. After solvents evaporation the solid was dried in oven at 400C under vacuum for 3 h to give pure (IR)-I -[(4- trifluoromethanesulfonyloxy)phenyl]ethylamine hydrochloride as white powder (6.69 g, 75% yield), m.p. 210-2130C; [α]D 25 (c=0.5, CH3OH): +6.5°; 1H-NMR (DMSO-de) δ 8.60 (bs, 3H, NH3 +), 7.75 (d, 2H, J = 7Hz), 7.54 (d, 2H, J = 7Hz), 4.50 (m, IH), 1.54 (d, 3H, J = 7Hz). Following the procedure above described and starting from the appropriate carboxylic acids, the following amines were prepared:
(lR)-l-[(3-benzoyl)phenyl]ethylamine hydrochloride; white off powder; m.p. 200-2030C; [α]D 25 (c=0.5, CH3OH): +10°; 1H-NMR (CDCl3) δ 9.15 (bs, 3H, NH3 +), 8.12 (m, 2H), 7.95-7.80 (m, 3H), 7.70-7.55 (m, 4H), 4.60 (m, IH), 1.65 (d, 3H, J = 7Hz).
(lR)-l-[(3-furoyl)phenyl]ethylamine hydrochloride; pale brown powder; m.p. 115-117°C; [α]D 25 (c=0.3, CH3OH): +7°; 1H-NMR (CDCl3) δ 8.90 (bs, 3H, NH3 +), 8.12 (s, IH), 7.90 (d, IH, J =7Hz ), 7.80 (d, IH, J = 7Hz), 7.70 (s, IH), 7.48 (t, IH, J = 7Hz), 7.35 (d, IH, J = 7Hz), 6.60 (m, IH), 4.55 (m, IH), 1.80 (d, 3H, J = 7Hz). Example 1
Synthesis of (lR)-l-arylethanesulfonamides (Compounds 1-8) 4-{(lR)-l-[(Phenylsulfonyl)amino]ethyl}phenyl trifluoromethanesulfonate (1). To a solution of (lR)-l-[(4-trifluoromethanesulfonyloxy)phenyl]ethylamine hydrochloride (0.2 g, 0.65 mmol) in dry CH2Cl2 (3 mL), Na2CO3 (0.15 g, 1.44 mmol) and benzenesulfonyl chloride (92 μL, 0.72 mmol) were added and the resulting mixture was left stirring at room temperature overnight. The reaction was quenched by adding a NaH2PO4 buffer solution (pH 4.1-4.5) (5 mL) and EtOAc (10 mL). The two phases were separated and the organic one was dried over Na2SO4, filtered and evaporated under vacuum to give an oily residue. 1 was obtained pure after purification by flash chromatography (CHC13/CH3OH 9: 1) as a glassy solid (0.18 g, 68% yield). [α]D 25 (c=3, CH3OH): +35°; 1H-NMR (CDCl3) δ 7.70 (d, 2H, J = 7Hz), 7.62 (m, IH), 7.35 (d, 2H, J = 7Hz), 7.18 (d, 2H, J = 7Hz), 7.05 (d, 2H, J = 7Hz), 4.95 (bs, IH, NH), 4.58 (q, IH, J = 7Hz), 1.40 (d, 3H, J = 7Hz).
Following the procedure above described and starting from the described (IR)-I- arylethanamines and from the requested sulfonyl chlorides, the following 1- arylethanesulfonamides were prepared:
N-[(lR)-l-(3-Benzoylphenyl)ethyl]benzenesulfonamide (2); waxy solid; [CC]D 25 (c=0.4, CH3OH): +48.5°; 1H-NMR (CDCl3) δ 7.85 (m, IH), 7.78 (d, 3H, J = 7Hz), 7.65 (m, 2H), 7.50-7.40 (m, 4H), 7.35-7.25 (m, 4H), 4.80 (bs, IH, NH), 4.60 (q, IH, J = 7Hz), 1.47 (d, 3H, J = 7Hz).
4-{(lR)-l-[(Pyridine-3-ylsulfonyl)amino]ethyl} phenyl trifluoromethanesulfonate (3); waxy solid; [α]D 25 (c=3, CH3OH): +27°; 1H-NMR (CDCl3) δ 9.28 (s, IH), 8.65 (d, IH, J = 7Hz), 7.95 (d, IH, J = 7Hz), 7.40 (m, IH), 7.30 (d, 2H, J = 7Hz), 7.10 (d, 2H, J = 7Hz), 6.30 (bs, IH, NH), 4.72 (q, IH, J = 7Hz), 1.53 (d, 3H, J = 7Hz). N-[(lR)-l-(3-Benzoylphenyl)ethyl]methanesulfonamide (4); yellow oil; [CC]D 25 (c=l, CH3OH): +45.5°; 1H-NMR (CDCl3) δ 7.92-7.80 (m, 3H), 7.75 (m, IH), 7.65- 7.58 (m, 2H), 7.52-7.45 (m, 3H), 4.80 (q, IH, J = 7Hz), 4.65 (bs, IH, NH), 2.80 (s, 3H), 1.72 (d, 3H, J = 7Hz). N-[(lR)-l-[3-(2-Furoyl)phenyl]ethyl}thiophene-2-sulfonamide (5); white powder; m.p. 105-1060C; [α]D 25 (c=l, CH3OH): +72°; 1H-NMR (CDCl3) δ 7.85 (d, IH, J = 7Hz), 7.70 (d, 2H, J = 7Hz), 7.50-7.38 (m, 3H), 7.20 (d, IH, J = 3Hz), 6.95 (d, IH, J = 3Hz), 6.65 (m, IH), 4.90 (bs, IH, NH), 4.68 (q, IH, J = 7Hz), 1.55 (d, 3H, J = 7Hz). N-[(lR)-l-[3-(2-Furoyl)phenyl]ethyl}methanesulfonamide ( 6); yellow oil; [α]D 25 (c=0.3, CH3OH): +48°; 1H-NMR (CDCl3) δ 8.02-7.90 (m, 2H), 7,75 (m, IH), 7.60 (m, IH), 7.42-7.35 (m, IH), 7.28 (m, IH), 6.65 (m, IH), 4.80 (q, IH, J = 7Hz), 4.65 (bs, IH, NH), 2.75 (s, 3H), 1.65 (d, 3H, J = 7Hz).
4-{(lR)-l-[(Thien-2-ylsulfonyl)amino]ethyl} phenyl trifluoromethanesulfonate (7); colourless oil; [α]D 25 (c=0.6, CH3OH): +31°; 1H-NMR (CDCl3) δ 7.55 (d, IH, J = 7Hz), 7.40 (d, IH, J = 7Hz), 7.30 (d, 2H, J = 7Hz), 7.10 (d, 2H, J = 7Hz), 6.95 (m, IH), 4.95 (bs, IH, NH), 4.65 (q, IH, J = 7Hz), 1.45 (d, 3H, J = 7Hz). N-[(lR)-l-(3-Benzoylphenyl]ethyl}thiophene-2-sulfonamide (8); colourless oil; [CC]D 25 (C=0.6, CH3OH): +67°; 1H-NMR (CDCl3) δ 7.80-7.70 (m, 2H), 7.68-7.55 (m, 3H), 7.50-7.42 (m, 5H), 7.35 (t, IH, J = 7Hz), 6.90 (t, IH, J = 7Hz ), 5.15 (bs, IH, NH), 4.65 (q, IH, J = 7Hz), 1.50 (d, 3H, J = 7Hz). Example 2
N-[(lR)-l-(3-Benzoylphenyl]ethyl}-3-pyrrolidin-l-ylpropane-l-sulfonamide hydrochloride (9) A. Preparation ofN-[(lR)-l-(3-benzoylphenyl)ethyl]ethylenesulfonamide.
To a solution of (lR)-l-[(3-benzoyl)phenyl]ethylamine hydrochloride (0.3 g, 1.14 mmol) in dry CH2Cl2 (10 mL), triethylamine (0.36 mL, 2.51 mmol) and 2- chloroethanesulfonyl chloride (0.14 mL, 1.37 mmol) were added, and the resulting mixture was left stirring at room temperature for 2 h. The reaction was quenched by adding H2O (10 mL). The two phases were separated and the organic one washed with IN HCl (2 x 5 mL), dried over Na2SO4, filtered and evaporated under vacuum to give the intermediate N-[(lR)-l-(3-benzoylphenyl)ethyl]ethylenesulfonamide as an oily residue (0.3 g, 75% yield), pure enough for the next step. 1H-NMR (CDCl3) δ 7.95-7-75 (m, 3H), 7.60 (d, IH, J = 7Hz), 7.55-7.40 (m, 5H), 6.35 (m, IH), 6.20 (d, IH, J = 15Hz), 5.75 (d, IH, J = 8Hz), 4.65 (m, IH + NH), 1.60 (d, 3H, J = 7Hz). B. Preparation of compound 9.
To a solution of N-[(lR)-l-(3-benzoylphenyl)ethyl]ethylenesulfonamide (0.28 g, 0.81 mmol) and triethylamine (0.11 mL, 0.81 mmol) in acetone (10 mL), pyrrolidine (68 μL, 0.81 mmol) was added by dripping. The resulting solution was left stirring at room temperature for 1 h and then refluxed for 3 h. After solvent evaporation the residue was diluted with IN HCl (5 mL) and washed with Et2O (2 x 5 mL) and then with CHCl3 (3 x 5 mL). The collected organic extracts in CHCl3 were dried over Na2SO4, filtered and evaporated under vacuum to give a residue that, after purification by flash chromatography (CHC13/CH3OH 95:5), afforded the pure compound 9 as pale yellow oil (0.28 g, 82% yield). [α]D 25 (c=0.3, CH3OH): +21°; 1H-NMR (DMSO-de) δ 10.40 (bs, IH, NH+), 8.18 (bs, IH, NH), 7.80-7.70 (m, 2H), 7.68-7.55 (m, 3H), 7.50-7.42 (m, 4H), 4.65 (q, IH, J = 7Hz), 3.60-3.40 (m, 6H), 2.95
(m, 2H), 1.97-1.78 (m, 4H), 1.45 (d, 3H, J = 7Hz).
Example 3
Methyl 5-({[(lR)-l-(3-benzoylphenyl)ethyl]amino}sulfonyl)-2-furoate (10) A. Preparation of5-(methoxycarbonyl)furan-2-sulfonate sodium salt.
A solution of 2-furoyl chloride (1.5 g, 11.5 mmol) in CH3OH (20 mL) was left stirring at room temperature for 24 h. After solvent evaporation under vacuum, the crude residue was diluted with CHCl3 (15 mL), washed with a saturated solution of NaHCO3 (2 x 10 mL) and with H2O (10 mL), dried over Na2SO4 and evaporated under vacuum to give methyl 2-furoate as yellow oil (1.4 g, 97% yield). The ester was dissolved in fuming H2SO4 (0.2 mL) and left stirring overnight at room temperature. Crushed ice and cool H2O (5 mL) were carefully added, and then BaCO3 was added (1.13 g, 5.75 mmol). The resulting suspension was heated to reflux and until the almost complete salt dissolution (3 h). After cooling at room temperature, barium sulfate was filtered off and the filtrate was evaporated under reduced pressure to give a crude which was diluted with 96% EtOH (30 mL) and refluxed for 2 h. The precipitate was filtered while hot and treated with a solution of Na2CO3 to pH 7.5-8.0; the formed precipitate (barium sulfate) was filtered off and the mother liquors evaporated under vacuum to give the intermediate 5- (methoxycarbonyl)furan-2-sulfonate sodium salt (1.325 g, 50% yield). 1H-NMR (D2O) δ 7.05 (d, IH, J = 7Hz), 6.80 (d, IH, J = 7Hz), 3.82 (s, 3H). 5-(methoxycarbonyl)furan-2-sulfonate sodium salt (0.50 g, 2.19 mmol) was dissolved in PCl5 (0.91 g, 4.38 mmol) and the mixture was left at 1500C for 3 h, until the disappearance of the starting material (GC-Ms analysis). After cooling at room temperature, crushed ice and cool H2O were added and the aqueous phase was extracted with CHCl3 (2 x 10 mL); the collected organic extracts were dried over Na2SO4, filtered and evaporated under vacuum to give the intermediate sulfonyl chloride (0.21 g, 0.95 mmol) used for the next step without any further purification. B. Preparation of compound 10. To a solution of (lR)-l-[(3-benzoyl)phenyl]ethylamine hydrochloride (0.22 g, 0.85 mmol) and triethylamine (0.24 m L, 1.8 mmol) in dry CH2Cl2 (2 mL), a solution of the sulfonyl chloride (0.21 g, 0.95 mmol) in dry CH2Cl2 (2 mL) was added by dripping. The resulting solution was left stirring at room temperature overnight. After solvent evaporation the crude oily residue was purified by flash chromatography (CHCVn-hexane/CHsOH 80:20: 1) and the pure compound 10 was isolated as white powder (0.14 g, 40% yield). [α]D 25 (c=0.2, CH2Cl2): -5°; 1H-NMR (CDCl3) δ 7.75 (d, 2H, J = 7Hz), 7.60 (d, 3H, J = 7Hz), 7.50-7.35 (m, 3H), 7.30 (m, IH), 6.95 (d, IH, J = 7Hz), 6.80 (d, IH, J = 7Hz), 5.20 (bs, IH, NH), 4.70 (q, IH, J = 7Hz), 3.85 (s, 3H), 1.55 (d, 3H, J = 7Hz). Example 4 5-({[(lR)-l-(3-Benzoylphenyl)ethyl]amino}sulfonyl)-2-furoic acid (11)
To a solution of methyl 5-({[(lR)-l-(3-benzoylphenyl)ethyl]amino}sulfonyl)-2- furoate (0.1 g, 0.24 mmol) in glacial AcOH (10 mL) few drops of 37% HCl were added and the resulting solution was refluxed for 12 h. After cooling at room temperature solvents were evaporated under vacuum, the residue was diluted with a saturated solution Of NaHCO3 (10 mL), washed with CHCl3 (2 x 5 mL), acidified to pH 1 by 37% HCl and extracted again with CHCl3 (2 x 5 mL). The collected organic extracts were dried over Na2SO4, filtered and evaporated under vacuum to give the pure compound 11 as a waxy solid (0.075 g, 78% yield). [α]D 25 (c=0.5, CH2Cl2): - 12°; 1H-NMR (CDCl3) δ 7.75 (d, 2H, J = 7Hz), 7.60 (d, 3H, J = 7Hz), 7.50-7.35 (m, 3H), 7.30 (m, IH), 7.05 (d, IH, J = 7Hz), 6.85 (d, IH, J = 7Hz), 5.75 (bs, IH, NH), 4.78 (q, IH, J = 7Hz), 4.50 (bs, IH, COOH), 1.57 (d, 3H, J = 7Hz). Example 5
4-{(lR)-2-Methyl-l-[(methylsulfonyl)amino]propyl}phenyl trifluoromethanesulfonate (12) A. Preparation of (2R)-3-methyl-2-[4(trifluoromethylsulfonyloxy)phenyl]butanoic acid. To a solution of commercial 2-(4-chlorophenyl)-3-methylbutyric acid (1 g, 4.7 mmol) in CH3OH (10 mL), few drops of cone. H2SO4 were added, and the resulting mixture was left stirring at room temperature overnight. After solvent evaporation under vacuum, CH2Cl2 (10 mL) and H2O (10 mL) were added; the two phases were separated and the organic one dried over Na2SO4, filtered and evaporated under vacuum to give the intermediate methyl 2-(4-chlorophenyl)-3-methylbutanoate as an oily residue (quantitative yield). This intermediate was transformed in the related methyl 2-(4-hydroxyphenyl)-3-methylbutanoate according a known procedure3: a mixture of methyl 2-(4-chlorophenyl)-3-methylbutanoate (1.06 g, 4.7 mmol), 60% sodium hydride (0.56 g, 14.1 mmol) and H2O (85 μL, 4.7 mmol) was heated to 45°C while kept at argon atmosphere for 3 days (1H-NMR analysis). The solvent was evaporated and the residue diluted with EtOAc and washed with IN HCl (2 x 5 mL); the solvent was evaporated under vacuum and the crude residue was purified by flash chromatography (CHCI3/CH3OH 85: 15) to give the pure intermediate as an oil (0.75 g, 77% yield). 1H-NMR (CDCl3) δ 7.18 (d, 2H, J = 7Hz), 6.82 (d, 2H, J = 7Hz), 5.75 (bs, IH, OH), 3.70 (s, 3H), 3.15 (d, IH, J = 14Hz), 2.55 (m, IH), 1.10 (d, 3H, J = 7Hz), 0.72 (d, 3H, J = 7Hz). The steps of insertion of the triflate group and the following hydrolysis were performed as described1 and 3-methyl-2-[4- (trifluoromethylsulfonyloxy)phenyl]butanoic acid was obtained as a colourless oil (0.91 g, 78% yield calculated from the 4-hydroxy methyl ester derivative). The optical resolution was performed as described.4 (2R)-3-methyl-2-[4- (trifluoromethylsulfonyloxy)phenyl]butanoic acid (0.32 g, 35% yield) was obtained as a white solid. [α]D 25 (c=l, CH3OH): -50°; 1H-NMR (CDCl3) δ 7.55 (d, 2H, J = 7Hz), 7.25 (d, 2H, J = 7Hz), 3.15 (d, IH, J = 14Hz), 2.55 (m, IH), 1.10 (d, 3H, J = 7Hz), 0.72 (d, 3H, J = 7Hz). B. The synthesis of compound 12 was performed as above described for compound 1. 4-{(lR)-2-methyl-l-[(methylsulfonyl)amino]propyl}phenyl trifluoro methane sulfonate was obtained as pale yellow oil. [α]D 25 (c=0.5, CH3OH): +15°; 1H-NMR (CDCl3) δ 7.55 (d, 2H, J = 7Hz), 7,25 (d, 2H, J = 7Hz), 4.80 (m, IH), 4.60 (bs, IH, NH), 2.75 (s, 3H), 2.55 (m, IH), 1.10 (d, 3H, J = 7Hz), 0.72 (d, 3H, J = 7Hz). Example 6
N-((lR)-l-{4-[l-methyl-l-(phenylsulfonyl)ethyl]phenyl}ethyl) methanesulfonamide (13)
A. Preparation of N-((lR)-l-{4-[l-methyl-l-(phenylsulfonyl)ethyl]phenyl}propanoic acid. 4-Iodophenylpropanenitrile was synthesised by known procedure5 starting from the commercial 4-iodophenylacetonitrile. To a cooled (-780C) solution of 4- iodophenylpropanenitrile (0.26 g, 1 mmol) in dry THF (10 mL), isopropylmagnesium chloride (2M solution in THF) (1 mL, 2 mmol) and acetone (147 μL, 2 mmol) were added and the resulting mixture was left to raise to room temperature and stirring overnight. The reaction was quenched by adding a saturated solution Of NH4Cl (10 mL) and the aqueous phase was extracted with Et2O (3 x 20 mL); the collected organic extracts, after drying over Na2SO4, were filtered and evaporated under vacuum to give a crude residue that, after purification by flash chromatography (n-hexane/EtOAc 9:1), afforded the intermediate 2- [4-(l -hydroxy- 1- methylethyl)phenyl]propanenitrile (0.11 g, 60% yield) as colourless oil. 1H-NMR (CDCl3) δ 7.45 (d, 2H, J = 7Hz), 7,20 (d, 2H, J = 7Hz), 3.90 (m, IH), 2.05 (bs, IH, OH), 1.70 (d, 3H, J = 7Hz), 1.55 (s, 6H). The following acid hydrolysis (AcOH/HCl/reflux/4 h) and the optical resolution4 of the racemic acid afforded the (2R)-2-[4-(l -hydroxy- l-methylethyl)phenyl]propanoic acid as white solid. [CC]D 25 (c=l, CH3OH): -12°; 1H-NMR (CDCl3) δ 7.45 (d, 2H, J = 7Hz), 7.20 (d, 2H, J = 7Hz), 3.45 (m, IH), 2.05 (bs, IH, OH), 1.55 (s, 6H), 1.50 (d, 3H, J = 7Hz). A solution of the related methyl ester (0.22 g, 1 mmol) in CH2Cl2 (2 mL) was then reacted with thiophenol (0.12 mL, 1.2 mmol) according a described procedure6 to obtain, after purification by flash chromatography and methyl ester hydrolysis, (2R)- 2-{4-[l-methyl-l-(phenylthio)ethyl]phenyl}propanoic acid was obtained as pale yellow oil (0.18 g, 60% yield). 1H-NMR (CDCl3) δ 7.45 (d, 2H, J = 7Hz), 7.25 (d, 2H, J = 7Hz), 7.20-7.05 (m, 5H), 3.45 (m, IH), 1.50 (d, 3H, J = 7Hz), 1.25 (s, 6H). The oxidation of the sulfide to sulfone was accomplished according a published procedure.7 To a cooled (0-50C) solution of the acid (0.15 g, 0.5 mmol) in CH3OH (5 mL) magnesium bis(monoperoxyphtalate hexahydrate (MMPP) (0.5 g, 1 mmol) was added and the resulting mixture was left stirring for 4 h. After solvent evaporation under vacuum, the crude residue was purified by flash chromatography (n- hexane/EtOAc 8:2) to afford N-((1R)- l-{4-[l -methyl- 1-
(phenylsulfonyl)ethyl]phenyl}propanoic acid as a colourless oil (0.18 g, 55% yield). [CC]D 25 (C=1, CH3OH): -32°; 1H-NMR (CDCl3) δ 7.45 (d, 2H, J = 7Hz), 7.30-7.15 (m, 7H), 3.45 (m, IH), 1.75 (s, 6H), 1.50 (d, 3H, J = 7Hz). B. The synthesis of compound 13 was performed as above described for compound 1. N-((lR)-l-{4-[l-methyl-l-(phenylsulfonyl) ethyl] phenyl} ethyl) methane sulfonamide was obtained as colourless oil. [α]D 25 (c=0.5, CH3OH): +5°; 1H-NMR (CDCl3) δ 7.45 (d, 2H, J = 7Hz), 7.30-7.15 (m, 7H), 4.65 (m, IH), 4.40 (bs, IH, NH), 2.62 (s, 3H), 1.75 (s, 6H), 1.48 (d, 3H, J = 7Hz). Example 7
Preparation of (lR)-l-arylethylamides (compounds 14-20). 4-[(lR)-l-(Isobutyrylamino)ethyl]phenyl trifluoromethanesulfonate (14) To a solution of (lR)-l-[(4-trifluoromethanesulfonyloxy)phenyl]ethylamine hydrochloride (0.2 g, 0.65 mmol) in pyridine (5 mL), isobutyryl chloride (75 μL, 0.72 mmol) was added and the resulting mixture was refluxed for 1 h. After cooling at room temperature, the solvent was evaporated under vacuum and the crude residue diluted with EtOAc (5 mL) and washed with IN HCl (2 x 10 mL). The organic phase was dried over Na2SO4, filtered and evaporated under vacuum to give an oily residue. 14 was obtained pure after purification by flash chromatography (CHC13/CH3OH 95:5) as a colourless oil (0.165 g, 75% yield). [α]D 25 (c=0.5, CH3OH): +10°; 1H-NMR (CDCl3) δ 7.45 (d, 2H, J = 7Hz), 7.30 (d, 2H, J = 7Hz), 5.70 (bs, IH, NH), 5.15 (q, IH, J = 7Hz), 2.35 (m, IH), 1.52 (d, 3H, J = 7Hz), 1.15 (d, 6H, J = 7Hz). Following the procedure above described and starting from the described (IR)-I- arylethanamines and from the requested acyl chlorides, the following 1- arylethylamides were prepared:
4-{[(lR)-l-(Pyridine-J-ylcarbonyl )amino] ethyl]} phenyl trifluoro methane sulfonate ( 15); white powder; m.p. 120-1220C; [α]D 25 (c=l, CH3OH): -1.5°; 1H- NMR (CDCl3) δ 9.05 (s, IH), 8.78 (d, IH, J = 7Hz), 8.15 (d, IH, J = 7Hz), 7.50 (d, 2H, J = 7Hz), 7.35 (m, IH), 7.27 (d, 2H, J = 7Hz), 6.50 (bs, IH, NH), 5.35 (q, IH, J = 7Hz), 1.65 (d, 3H, J = 7Hz).
N-[(lR)-l-(3-Benzoylphenyl)ethyl]benzamide ( 16); colourless oil; [α]D 25 (c=0.5, CH3OH): +18°; 1H-NMR (CDCl3) δ 7.90 (m, IH), 7.80-7.70 (m, 4H), 7.65-7.52 (m, 4H), 7.45-7.30 (m, 5H), 6.40 (bs, IH, NH), 5.35 (q, IH, J = 7Hz), 1.65 (d, 3H, J = 7Hz).
N-[(lR)-l-(3-Benzoylphenyl)ethyl]-2-furamide (17); pale yellow oil; [α]D 25 (c=1.7, CH3OH): -50.5°; 1H-NMR (CDCl3) δ 7.90 (s, IH), 7.78 (d, 2H, J = 7Hz), 7.70-7.55 (m, 3H), 7.45 (m, 4H), 7.14 (d, IH, J = 3Hz), 6.58 (bs, IH, NH), 6.50 (d, IH, J = 3Hz), 5.35 (q, IH, J = 7Hz), 1.68 (d, 3H, J = 7Hz).
N-[(lR)-l-(3-Benzoylphenyl)ethyl]cyclobutanecarboxamide (18); white solid; m.p. 90-930C; [α]D 25 (c=0.3, CH3OH): +91°; 1H-NMR (CDCl3) δ 7.80-7.70 (m, 4H), 7.65 (m, IH), 7.60-7.50 (m, 4H), 5.55 (bs, IH, NH), 5.20 (q, IH, J = 7Hz), 3.00 (m, IH), 2.35-2.10 (m, 4H), 2.05-1.80 (m, 2H), 1.45 (d, 3H, J = 7Hz). Example 9 (Compounds 19-20)
N-[(lR)-l-(4-trifluoromethanesulfonyloxy)phenylethyl]-4-piperidin-l- ylbutanamide (19)
A. Preparation of sodium 4-piperidin-l-ylbutanoate. To a solution of ethyl 4-chlorobutyrate (0.5 g, 3.32 mmol) in DMF (2 niL), piperidine (0.98 niL, 9.96 mmol), triethylamine (1.4 mL, 9.96 mmol) and a catalytic amount of KI were added and the resulting solution was refluxed overnight. After cooling at room temperature the solution was diluted with a saturated solution of NaHCO3 (10 mL) and extracts with Et2O (3 x 10 mL). The collected organic extracts were dried over Na2SO4, filtered and evaporated under vacuum to give the ethyl 4- piperidin-1-ylbutanoate as an oily residue (0.6 g, 3 mmol) pure enough for the next step. To a solution of the ester in dioxane (5 mL), few drops of 37% HCl were added and the solution was refluxed overnight. After cooling at room temperature the solvent was evaporated under vacuum and the residue was dried overnight in oven at 600C in vacuo. The crude 4-piperidin-l-ylbutanoic acid was dissolved in CH3OH (4 mL) and NaHCO3 (0.5 g, 6 mmol) was added. After stirring for 2 h, the precipitate was filtered off and the mother liquors concentrated to afford the intermediate sodium 4-piperidin-l-ylbutanoate (0.55 g, 2.84 mmol) as a colourless oil. 1H-NMR (DMSO-de) δ 3.35 (m, 2H), 2.80 (m, 2H), 2.70 (m, 2H), 2.15 (t, 2H, J = 3Hz), 1.95 (m, 2H), 1.75 (m, 6H).
B. Preparation of compound 15. To a solution of sodium 4-piperidin-l-ylbutanoate (0.41 g, 2.13 mmol) in dry CH2Cl2 (10 mL), l,r-carbonyldiimidazole (0.34 g, 2.13 mmol) was added and the resulting solution was left stirring at room temperature for 1 h. Triethylamine (0.59 mL, 4.25 mmol) and (lR)-l-[(4-trifluoromethanesulfonyloxy)phenyl]ethylamine hydrochloride (0.65 g, 2.13 mmol) were added and the resukting solution was left stirring at room temperature overnight. A saturated solution OfNaHCO3 (10 mL) was added and the two phases separated. The organic one was washed with extracts with a saturated solution of NaHCO3 (2 x 5 mL), dried over Na2SO4, filtered and evaporated under vacuum to give an oily residue. The crude was purified by flash chromatography (CHCl3/CH3OH/cyclohexane/NH4OH 60: 14:24:2) and the eluted free base, after treatment with an excess of acetyl chloride in EtOH (1.4 M), afforded N-[(lR)-l-(4-trifluoromethanesulfonyloxy)phenylethyl]-4-piperidin-l-ylbutanamide 15 in form of hydrochloride (0.734 g, 75% yield) as pale yellow oil. [CC]D 25 (C=0.3, CH3OH): +51.5°; 1H-NMR (DMSO-d6) δ 9.95 (bs, IH, NH+), 8.55 (bs, IH, NH), 7.45 (q, 4H, J = 7Hz), 4.90 (q, IH, J = 7Hz), 3.35 (m, 2H), 2.92 (m, 2H), 2.80 (m, 2H), 2.25 (t, 2H, J = 3Hz), 1.95 (m, 2H), 1.75 (m, 6H).
4-{(lR) -1- [(4-pyrrolidin-l-ylbutanoyl) amino] ethyl]} phenyl trifluoro methane sulfonate (20) The synthesis of compound 20 was performed as above described for compound 19. 4- ((1R)- 1 -[(4-pyrrolidin- 1 -ylbutanoyl)amino]ethyl] }phenyl trifluoromethanesulfonate was obtained as colourless oil. [CC]D 25 (C=0.1, CH3OH): +40°; 1H-NMR (CDCl3) δ 7.60 (bs, IH, NH), 7.40 (d, 2H, J = 7Hz), 7.25 (d, 2H, J = 7Hz), 5.15 (q, IH, J = 7Hz), 2.55 (m, 6H), 2.35 (t, 2H, J=3Hz), 1.85-1.70 (m, 6H), 1.45 (d, 3H, J = 7Hz). Example 10
(3-{(lR) -1- [ (4-trifluoromethyl-l,3-thiazol-2-yl) amino] ethyl]} phenyl) (phenyl) methanone (21)
To a solution of (lR)-l-[(3-benzoyl)phenyl]ethylamine hydrochloride (0.52 g, 2 mmol) in toluene (15 mL), cone. H2SO4 (3 mmol) and sodium thiocyanate (0.18 g, 2.2 mmol) were added and the resulting mixture was left stirring at room temperature for 30 min. The formation of a white precipitate was observed: then the mixture was refluxed for 4 h and left stirring at room temperature overnight. The organic phase was washed with H2O (3 x mL), dried over Na2SO4, filtered and evaporated under vacuum to give the N-[(lR)-l-(3-benzoylphenyl)ethyl]thiourea a dark red oil (0.53 g) pure enough (GC-Ms analysis) to be used without any further purification. To a solution of thiourea (0.2 g, 0.7 mmol) in dry THF (10 mL) 3-bromo-l,l,l- trifluoroacetone (0.27 g, 1.4 mmol) and the resulting solution was left stirring at 400C overnight. After cooling at room temperature, the solution was evaporated under vacuum and the crude was diluted with EtOAc (20 mL) and a saturated solution Of NaHCO3 (15 mL); The two phases were separated and the organic one was washed with a saturated soliution of NaCl, dried over Na2SO4, filtered and evaporated under vacuum to give a crude that, after purification by flash chromatography (eluent mixture n-hexane/EtOAc 9: 1), afforded 21 (0.185 g, 70% yield) as colourless oil. [α]D 25 (c=0.1, CH3OH): +44°; 1H-NMR (CDCl3) δ 7.80-7.70 (m, 4H), 7.65 (m, 2H), 7.60-7.50 (m, 3H), 6.90 (s, IH), 5.75 (bs, IH, NH), 4.80 (q, IH, J = 7Hz), 1.65 (d, 3H, J = 7Hz).
References
1- Aureli L. et al. J. Med. Chem., 2005, 48, 2469. 2- Banthorpe D.V. in Patai The Chemistry of the Azido Group ; Wiley : NY,
1971, 397.
3- Widdowson K.L. et al., US 6,608,077 (19/08/2003).
4- Akgun, H. et al., Arzneimittelforschung, 1996, 46, 891.
5- Kaltenbronn J.S. J. Med. Chem., 1973, 16, 490. 6- Gauthier J. Y. et al., Tetrahedron Lett. , 1986, 27, 15.
7- (a) Arjona O. et al., J. Org. Chem., 2001, 66, 2400. (b) Arjona O. et al., Tetrahedron, 2001, 57, 6751. Table 1. Compounds active on PMNs C5a induced chemotaxis
Figure imgf000025_0001

Claims

1. (R)-Arylalkylamino derivatives of formula (I):
Figure imgf000026_0001
(I) wherein
R is selected from:
- 2 -thiazolyl or 2-oxazolyl, unsubstituted or substituted by a group selected from methyl, tert -butyl or trifluorom ethyl group;
- C(Ra)=N-W wherein W is linear or branched C1-C4 alkyl,
- CORa, SORa, SO2Ra, PORd, PO2Ra, wherein
Ra is selected from - Ci-Cs-alkyl, C3-C6-cycloalkyl, C2-Cs-alkenyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, halo-Ci-C4-alkoxy, hydroxy, Ci-C4-acyloxy, phenoxy, cyano, nitro, amino;
- a heteroaryl group selected from pyridine, pyrimidine, pyrrole, thiophene, furane, indole, thiazole, oxazole, such heteroaryl being unsubstituted or substituted with a group selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, halo-Ci-C4-alkoxy, hydroxy, C1-C4- acyloxy, phenoxy, cyano, nitro, amino;
- a α or β carboxyalkyl residue consisting of straight or branched C1- Ce-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, CrCe-phenylalkyl, optionally substituted with a further carboxy (COOH) group;
- an ω-aminoalkylamino group of formula II: R2
— X- N \
R3
(H) wherein
X represents: - linear or branched C1-C6 alkylene, C4-C6 alkenylene, C4-C6 alkynylene, optionally substituted by a CO2R4 group or by a C0NHR5 group, wherein R4 represents hydrogen or a linear or branched Ci-C6 alkyl group or a linear or branched C2-C6 alkenylgroup, wherein R5 represents hydrogen, linear or branched C2- C6 alkyl or an OR4 group, R4 being defined as above;
- a (CH2)m-B-(CH2)n, group, optionally substituted by a CO2R4 or C0NHR5 group, as defined above, wherein B is an oxygen, or sulfur atom, or nitrogen atom optionally substituted by a Ci-C4 alkyl group, m is zero or an integer from 2 to 3 and n is an integer from 2 to 3, or B is a CO, SO or CONH group, m is an integer from 1 to 3 and n is an integer from 2 to 3;
- or X together with the nitrogen atom to which it is bound and with the R2 group forms a nitrogen containing 3-7 membered heterocyclic, monocyclic or poly cyclic ring, and R3 represents hydrogen, Ci-C4 alkyl, Ci-C4 acyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, hydroxy, C1-C4- acyloxy, phenoxy, cyano, nitro, amino; R2 and R3 are independently: hydrogen, linear or branched Ci-C6 alkyl, optionally interrupted by an oxygen or sulfur atom, a C3-C7 cycloalkyl, C3-C6 alkenyl, C3-
C6-alkynyl, aryl-Ci-C3-alkyl, hydroxy-C2-C3-alkyl group; or R2 and R3 together with the N atom to which they are bound, form a 3-7 membered nitrogen heterocyclic ring of formula (III)
Figure imgf000028_0001
wherein
Y represents:
- a single bond, CH2, O, S, or a N-R6 group, where R6 represents hydrogen, Ci-C4 alkyl, Ci-C4 acyl, unsubstituted or substituted phenyl with a group selected from halogen, Ci-C4-alkyl, C1-C4- alkoxy, hydroxy, Ci-C4-acyloxy, phenoxy, cyano, nitro, amino, and p represents an integer from 0 to 3;
- a residue of formula SO2R7 wherein R7 is Ci-Cδ-alkyl, C3-C6- cycloalkyl, C2-C6-alkenyl, aryl and heteroaryl;
Rl is linear or branched C1-C5 alkyl, C3-Cs cycloalkyl;
Ar is a phenyl group unsubstituted or substituted by one or more groups independently selected from halogen, Ci-C4-alkyl, Ci-C4-alkoxy, hydroxy, Ci-C4-acyloxy, phenoxy, cyano, nitro, amino, Ci-C4-acylamino, halo-Ci- C3- alkyl, halo-Ci-C3-alkoxy, benzoyl, heteroaryl carbonyl, heteroaryl, linear or branched Ci-Cg-alkanesulfonate, linear or branched C1-Cg- alkanesulfonamides, linear or branched Ci-Cs alkyl sulfonylmethyl; or Ar is a heteroaryl ring selected from pyridine, pyrrole, tiofene, furane, indole. Preferred compounds according to the invention are those wherein:
R is
- 2-thiazolyl, unsubstituted or substituted by a group selected from methyl or trifluoromethyl group;
- CORa, SO2Ra, SORa; wherein
Ra is selected from:
- Ci-C5-alkyl, C3-C5-cycloalkyl;
- phenyl, 2-pyridyl, 2-thiazolyl, 2-furyl, 2-pyrrolyl, 2-thiofenyl,
2-indolyl groups; - a carboxylalkyl group consisting of straight or branched Ci-C6-alkyl, Ci-C6- phenylalkyl group;
- an ω-alkylamino group of formula II,
R2
— X-U
\
R3 (II) wherein X represents: linear or branched Ci-C6 alkylene, C4-C6 alkenylene, C4-C6 alkynylene; or X together with the nitrogen atom to which it is bound and with the R2 group forms a nitrogen containing 3-7 membered heterocyclic monocyclic ring and R3 represents hydrogen or Ci-C4 alkyl;
R2 and R3 are independently hydrogen, linear or branched Ci-C6 alkyl, C3-C7 cycloalkyl, C3-C6 alkenyl, C3-C6-alkynyl; or R2 and R3 together with the N atom to which they are bound, form a 4-6 membered nitrogen containig heterocyclic ring of formula (III)
Figure imgf000029_0001
wherein Y represents CH2, O, S, or a N-R6 group, where R6 represents hydrogen, Ci-C4 alkyl, Ci-C4 acyl, and p represents an integer from 0 to 2; Rl is methyl; Ar is selected from:
3 ' -benzoylphenyl, 3 ' -(4-chloro-benzoyl)-phenyl, 3 ' -(4-methyl-benzoyl)-phenyl, 3 '-acetyl-phenyl, 3'-propionyl-phenyl, 3'-isobutanoyl-phenyl, 4'-isobutyl- phenyl, 4' -trifluoromethanesulfonyloxy-phenyl, 4'-benzenesulfonyloxy-phenyl, 4'-trifluoromethanesulfonylamino-phenyl, 4'-benzenesulfonylamino-phenyl, 4'-benzenesulfonylmethyl-phenyl, 4'-acetoxyphenyl, 4'-propionyloxy-phenyl,
4'-benzoyloxy-phenyl, 4'-acetylamino-phenyl, 4'-propionylamino-phenyl, 4'- benzoylamino-phenyl; 3 '-(furan-2-carbonyl)-phenyl; 3 '-(benzofuran-2-carbonyl)-phenyl; 3 '-(thiophen- 2-carbonyl)-phenyl; 3 ' -(pyridine-2-carbonyl)-phenyl, 3 ' -(thiazole-2-carbonyl)- phenyl, 3'-(oxazole-2-carbonyl)-phenyl; 3'-(2-furyl)-phenyl, 3'-(2-oxazolyl)- phenyl, 3'-(3-isoxazolyl)-phenyl, 3'-(2-benzoxazolyl)-phenyl, 3'-(3- benzoisoxazolyl)-phenyl, 3'-(2-thiazolyl)-phenyl, 3'-(2-pyridyl)-phenyl, 3'-(2- thiophenyl)-phenyl;
3. Preferred compounds of formula (I) are:
4- {(1R)- 1 -[(phenylsulfonyl)amino]ethyl }phenyl trifluoromethanesulfonate
N-[(lR)-l-(3-benzoylphenyl)ethyl]benzenesulfonamide 4-{(lR)-l-[(pyridine-3-ylsulfonyl)amino]ethyl}phenyl trifluoromethanesulfonate
N-[(lR)-l-(3-benzoylphenyl)ethyl]methanesulfonamide
N-[(lR)-l-[3-(2-furoyl)phenyl]ethyl}thiophene-2-sulfonamide
N-[(lR)-l-[3-(2-furoyl)phenyl]ethyl}methanesulfonamide
4- {(1R)- 1 -[(thien-2-ylsulfonyl)amino]ethyl }phenyl trifluoromethanesulfonate N-[(lR)-l-(3-benzoylphenyl]ethyl}thiophene-2-sulfonamide
N-[(lR)-l-(3-benzoylphenyl]ethyl}-3-pyrrolidin-l-ylpropane-l-sulfonamide methyl 5-({[(lR)-l-(3-benzoylphenyl)ethyl]amino}sulfonyl)-2-furoate
5-({[(lR)-l-(3-benzoylphenyl)ethyl]amino}sulfonyl)-2-furoic acid
4-{(lR)-2-methyl-l-[(methylsulfonyl)amino]propyl}phenyl trifluoromethanesulfonate
N-((lR)-l-{4-[l -methyl- l-(phenylsulfonyl)ethyl]phenyl}ethyl)methanesulfonamide
4-[(lR)-l-(isobutyrylamino)ethyl]phenyl trifluoromethanesulfonate
4-{[(lR)-l-(pyridine-3-ylcarbonyl)amino]ethyl]}phenyl trifluoromethanesulfonate
N-[(lR)-l-(3-benzoylphenyl)ethyl]benzamide N-[(lR)-l-(3-benzoylphenyl)ethyl]-2-furamide
N-[(lR)-l-(3-benzoylphenyl)ethyl]cyclobutanecarboxamide
N-[(lR)-l-(4-trifluoromethanesulfonyloxy)phenylethyl]-4-piperidin-l-ylbutanamide
4- {(1R)- 1 -[(4-pyrrolidin- 1 -ylbutanoyl)amino]ethyl] }phenyl trifluoromethanesulfonate (3-{(lR)-l-[(4-trifluoromethyl-l,3-thiazol-2-yl)amino]ethyl]}phenyl)
(phenyl)methanone 4 Compounds according to any of Claims 1 to 3, for use as medicaments
5 Use of compounds according to any of Claims 1 to 3 in the preparation of a medicament for the treatment of diseases that involve C5a induced human PMNs chemotaxis 6 Use of compounds according to any of Claims 1 to 3 in the preparation of a medicament for the treatment of sepsis, psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, glomerulonephritis and in the prevention and the treatment of injury caused by ischemia and reperfusion 7 Process for the preparation of intermediates (R)-arylalkylamines of formula (IV)
Figure imgf000031_0001
(IV)
wherein Ar and Rl are as defined in claim 1, comprising the steps of transforming the corresponding arylalkyl carboxylic acids in the acid azides, followed by the rearrangement of said azides in the corresponding isocyanates by Curtius reaction, and final conversion of isocyanates into amines by acidic hydrolysis 8. Process for the preparation of compounds of formula (I)
Figure imgf000031_0002
(I)
wherein R is CORa, SORa or SO2Ra, and Ra is as defined in claim 1, comprising the reaction between (R)-arylalkylamines of formula (IV) R1 ^H
Ar
(IV) wherein Ar and Rl are as defined in claim 1, with the corresponding acyl, sulfinyl or sulfonyl chlorides. 9. Pharmaceutical compositions comprising a compound according to Claims 1 to 3 in admixture and a suitable carrier thereof.
PCT/EP2006/068867 2005-11-24 2006-11-24 (r)-arylkylamino derivatives and pharmaceutical compositions containing them Ceased WO2007060215A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
RS20160819A RS55192B1 (en) 2005-11-24 2006-11-24 (R) -ARYLKYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2629935A CA2629935C (en) 2005-11-24 2006-11-24 (r)-arylalkylamino derivatives and pharmaceutical compositions containing them
ES06819736.7T ES2597843T3 (en) 2005-11-24 2006-11-24 Derivatives of (R) -arylalkylamino and pharmaceutical compositions containing them
EP06819736.7A EP1951663B1 (en) 2005-11-24 2006-11-24 (r)-arylkylamino derivatives and pharmaceutical compositions containing them
LTEP06819736.7T LT1951663T (en) 2005-11-24 2006-11-24 (r)-arylkylamino derivatives and pharmaceutical compositions containing them
JP2008541751A JP5374157B2 (en) 2005-11-24 2006-11-24 (R) -Arylalkylamino derivatives and pharmaceutical compositions containing them
SI200632098A SI1951663T1 (en) 2005-11-24 2006-11-24 (r)-arylkylamino derivatives and pharmaceutical compositions containing them
AU2006316452A AU2006316452B2 (en) 2005-11-24 2006-11-24 (R)-arylalkylamino derivatives and pharmaceutical compositions containing them
US12/094,837 US8026367B2 (en) 2005-11-24 2006-11-24 (R)-arylalkylamino derivatives and pharmaceutical compositions containing them
CN2006800515567A CN101360706B (en) 2005-11-24 2006-11-24 (R)-arylalkylamino derivatives and pharmaceutical compositions thereof
HRP20161260TT HRP20161260T1 (en) 2005-11-24 2006-11-24 (R) -ARYLKYLAMINE DERIVATIVES AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DK06819736.7T DK1951663T3 (en) 2005-11-24 2006-11-24 (r)-arylkylaminoderivater og farmaceutiske sammensætninger indeholdende dem
HK09106699.2A HK1127592B (en) 2005-11-24 2006-11-24 (r)-arylkylamino derivatives and pharmaceutical compositions containing them
CY20161101039T CY1118109T1 (en) 2005-11-24 2016-10-18 (R) -APYALKYLAMINO PRODUCERS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THESE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111257 2005-11-24
EP05111257.1 2005-11-24

Publications (2)

Publication Number Publication Date
WO2007060215A2 true WO2007060215A2 (en) 2007-05-31
WO2007060215A3 WO2007060215A3 (en) 2007-10-04

Family

ID=37865701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/068867 Ceased WO2007060215A2 (en) 2005-11-24 2006-11-24 (r)-arylkylamino derivatives and pharmaceutical compositions containing them

Country Status (18)

Country Link
US (1) US8026367B2 (en)
EP (1) EP1951663B1 (en)
JP (2) JP5374157B2 (en)
CN (1) CN101360706B (en)
AU (1) AU2006316452B2 (en)
CA (1) CA2629935C (en)
CY (1) CY1118109T1 (en)
DK (1) DK1951663T3 (en)
ES (1) ES2597843T3 (en)
HR (1) HRP20161260T1 (en)
HU (1) HUE031466T2 (en)
LT (1) LT1951663T (en)
PL (1) PL1951663T3 (en)
PT (1) PT1951663T (en)
RS (1) RS55192B1 (en)
RU (1) RU2458051C2 (en)
SI (1) SI1951663T1 (en)
WO (1) WO2007060215A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050258A1 (en) * 2007-10-18 2009-04-23 Dompé S.p.A. (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
RU2520212C2 (en) * 2008-09-18 2014-06-20 Домпе С.П.А. 2-arylpropionic acids and derivatives, and pharmaceutical compositions, containing thereof
US9145354B2 (en) 2011-11-01 2015-09-29 Astex Therapeutics Limited Pharmaceutical compounds
EP3498269A1 (en) 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
WO2019204505A3 (en) * 2018-04-18 2019-11-28 Theras, Inc. K-ras modulators with a vinyl sulfonamide moiety
EP4059497A1 (en) 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
WO2022195017A1 (en) 2021-03-17 2022-09-22 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4397306A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090028317A1 (en) * 2007-07-26 2009-01-29 The Directv Group, Inc. Method and system for providing callbacks from a user device using an ip network
US8793748B2 (en) * 2007-07-26 2014-07-29 The Directv Group, Inc. Method and system for controlling communication between a user device and a content delivery network
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
PT2585064T (en) 2010-06-24 2017-08-08 Chemocentryx Inc C5ar antagonists
NZ730123A (en) 2014-09-29 2023-05-26 Chemocentryx Inc Processes and intermediates in the preparation of c5ar antagonists
CN104623687B (en) * 2015-03-11 2017-09-05 中国科学院上海高等研究院 Antibody drug conjugate prepared by using maytansinol and its preparation method and application
CN108601790B (en) 2016-01-14 2026-01-27 凯莫森特里克斯股份有限公司 Method for treating C3 glomerulopathy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62252755A (en) * 1986-04-11 1987-11-04 Daikin Ind Ltd Novel n-benzylbenzamide derivative and herbicide containing said derivative as active component
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
JPH09301933A (en) * 1996-05-14 1997-11-25 Sumika Fine Chem Kk Production of amines
US6020335A (en) 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
US6455528B1 (en) * 1997-10-14 2002-09-24 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
AU750760B2 (en) * 1997-10-27 2002-07-25 Toyama Chemical Co. Ltd. Processes for producing 7-isoindolinequinolonecarboxylic derivatives and intermediates therefor, salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and composition containing the same as active ingredient
WO1999031048A1 (en) * 1997-12-15 1999-06-24 The Board Of Trustees Of The University Of Arkansas Fungicidal amides
IT1303249B1 (en) * 1998-10-23 2000-11-06 Dompe Spa SOME N- (2-ARYL-PROPIONYL) -SULPHONAMIDS AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM.
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
PL362546A1 (en) * 2000-10-05 2004-11-02 Fujisawa Pharmaceutical Co, Ltd. Benzamide compounds as apo b secretion inhibitors
ITMI20010395A1 (en) * 2001-02-27 2002-08-27 Dompe Spa OMEGA-AMINO ALKYLAMIDS OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF CHEMOTAXIS OF POLYMORPHONUCLEATED AND MONONUCLEATE CELLS
PL208928B1 (en) * 2001-04-16 2011-06-30 Pharmacopeia 3, 4-di-substituted cyclobuten-1, 2-diones as CXC chemokine receptor ligands
JP2005505595A (en) * 2001-10-12 2005-02-24 シェーリング　コーポレイション 3,4-Disubstituted maleimide compounds as CXC-chemokine receptor antagonists
AU2003900587A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US20050222408A1 (en) * 2003-07-14 2005-10-06 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
BRPI0413347A (en) * 2003-08-06 2006-10-10 Senomyx Inc new flavors, flavor modifiers, flavor agents, flavor enhancers, flavor agents and / or umami or sweet enhancers, and corresponding use
CA2550540A1 (en) * 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
GT200500013A (en) * 2004-01-23 2005-08-10 HERBICIDE AMIDAS
ATE444286T1 (en) * 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050258A1 (en) * 2007-10-18 2009-04-23 Dompé S.p.A. (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
US20100249198A1 (en) * 2007-10-18 2010-09-30 Dompe S.P.A (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
JP2011500643A (en) * 2007-10-18 2011-01-06 ドムペ・ソチエタ・ペル・アツィオーニ (R) -4- (Heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
US8133911B2 (en) 2007-10-18 2012-03-13 Dompe S.P.A (R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
CN101827841B (en) * 2007-10-18 2012-11-28 多派股份公司 (R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
RU2475486C2 (en) * 2007-10-18 2013-02-20 Домпе С.П.А. (r)-4-(heteroaryl)phenylehtyl derivatives and pharmaceutical compositions containing them
AU2008313669B2 (en) * 2007-10-18 2014-01-16 Dompe' Farmaceutici S.P.A. (R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
RU2520212C2 (en) * 2008-09-18 2014-06-20 Домпе С.П.А. 2-arylpropionic acids and derivatives, and pharmaceutical compositions, containing thereof
US9145354B2 (en) 2011-11-01 2015-09-29 Astex Therapeutics Limited Pharmaceutical compounds
EP3498269A1 (en) 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
WO2019115493A2 (en) 2017-12-12 2019-06-20 Dompe' Farmaceutici S.P.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
US12102607B2 (en) 2017-12-12 2024-10-01 Dompe' Farmaceutici S.P.A. C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
EP4706762A2 (en) 2017-12-12 2026-03-11 Dompé farmaceutici SpA C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
WO2019204505A3 (en) * 2018-04-18 2019-11-28 Theras, Inc. K-ras modulators with a vinyl sulfonamide moiety
EP4059497A1 (en) 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
WO2022195017A1 (en) 2021-03-17 2022-09-22 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4397306A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
WO2024146922A1 (en) 2023-01-05 2024-07-11 Dompe' Farmaceutici Spa C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Also Published As

Publication number Publication date
AU2006316452A1 (en) 2007-05-31
EP1951663A2 (en) 2008-08-06
RU2458051C2 (en) 2012-08-10
EP1951663B1 (en) 2016-07-20
WO2007060215A3 (en) 2007-10-04
SI1951663T1 (en) 2016-10-28
CN101360706B (en) 2013-10-02
HRP20161260T1 (en) 2016-11-18
JP2009517368A (en) 2009-04-30
US8026367B2 (en) 2011-09-27
JP5374157B2 (en) 2013-12-25
ES2597843T3 (en) 2017-01-23
LT1951663T (en) 2016-11-10
AU2006316452B2 (en) 2013-01-10
HUE031466T2 (en) 2017-07-28
RU2008125433A (en) 2009-12-27
CA2629935C (en) 2016-01-19
CN101360706A (en) 2009-02-04
JP5730343B2 (en) 2015-06-10
US20090124664A1 (en) 2009-05-14
HK1127592A1 (en) 2009-10-02
CA2629935A1 (en) 2007-05-31
DK1951663T3 (en) 2016-10-10
PL1951663T3 (en) 2017-01-31
JP2013173743A (en) 2013-09-05
RS55192B1 (en) 2017-01-31
PT1951663T (en) 2016-10-03
CY1118109T1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
JP5730343B2 (en) (R) -Arylalkylamino derivatives and pharmaceutical compositions containing them
ES2333445T3 (en) DERIVATIVES OF 2-PHENYLPROPIONIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0472449B1 (en) Substituted sulfonamides, processes for their preparation and medicines containing them
JP2009544620A (en) Prolineurea CCR1 antagonists for autoimmune diseases and inflammation
IL183932A (en) 2-arylpropionic acid derivatives, process for their preparation and their use in the manufacture of medicaments
EP1161415A2 (en) N-cyanomethylamides as protease inhibitors
JP2010504940A (en) Sulfonamide derivatives
US20050282871A1 (en) 3-(3,5-Disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
US20090215827A1 (en) Inhibitors of cxcr2
WO2012130299A1 (en) Peptidase inhibitors
HK1127592B (en) (r)-arylkylamino derivatives and pharmaceutical compositions containing them
AU728562B2 (en) Nitromethylthiobenzene derivatives as aldose reductase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2629935

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006316452

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008541751

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006316452

Country of ref document: AU

Date of ref document: 20061124

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2006819736

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006819736

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006316452

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008125433

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200680051556.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006819736

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12094837

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2016/0819

Country of ref document: RS